Drug Interaction Checker

Enter two or more drugs to check for known drug-drug interactions. The tool queries our interaction database and displays a severity matrix showing major, moderate, and minor interactions with clinical descriptions. Overall risk is calculated based on the combination of all interaction severities.

Search & Add Drugs

Results

Understanding Drug Interactions

Drug interactions occur when two or more drugs affect each other's pharmacokinetics or pharmacodynamics. Pharmacokinetic interactions alter how the body absorbs, distributes, metabolizes, or excretes a drug — often through the cytochrome P450 (CYP450) enzyme system in the liver. For example, CYP3A4 inhibitors like ketoconazole can dramatically increase plasma concentrations of co-administered drugs metabolized by the same enzyme, raising the risk of toxicity.

Pharmacodynamic interactions, by contrast, involve additive, synergistic, or antagonistic effects at the site of drug action without changing drug concentrations. Two CNS depressants taken together — such as benzodiazepines and opioids — produce synergistic respiratory depression far greater than either drug alone. Understanding which category an interaction falls into guides clinical management and dose adjustment decisions.

Interaction severity is typically classified as major (contraindicated or life-threatening), moderate (requires monitoring or dose adjustment), or minor (minimal clinical significance). High-risk combinations include anticoagulants with NSAIDs, MAOIs with serotonergic agents (serotonin syndrome risk), and QT-prolonging drugs given concurrently. Clinicians routinely screen for drug interactions when initiating new medications, especially in polypharmacy patients taking five or more drugs simultaneously.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

How to Use

1
Enter all current medications
Input the generic or brand name of each drug in your regimen, including prescription drugs, over-the-counter medications, and supplements. The checker cross-references each pair against FDA prescribing information and clinical pharmacology literature for documented interactions.
2
Review mechanism-based interaction alerts
For each flagged pair, the tool displays the interaction mechanism — CYP450 enzyme inhibition or induction, transporter-mediated effects, or pharmacodynamic convergence — along with the clinical consequence and severity rating from major to minor.
3
Use management recommendations
Each interaction alert includes evidence-based management guidance such as dose adjustment parameters, monitoring recommendations (e.g., INR checks for warfarin interactions), or suggested alternative agents. Share these recommendations with your pharmacist or prescriber for clinical review.

About

Drug-drug interaction pharmacology is grounded in the biochemical mechanisms governing drug metabolism and transport. The cytochrome P450 enzyme system, located primarily in hepatic endoplasmic reticulum and intestinal epithelium, catalyzes oxidative biotransformation of lipophilic drugs into more polar metabolites facilitating renal or biliary excretion. When two drugs share the same CYP isoform as substrate, competitive inhibition can reduce the clearance of one or both agents, raising plasma concentrations and the risk of dose-dependent toxicity. Induction of CYP enzymes through ligand-mediated upregulation of nuclear receptors such as PXR and CAR — exemplified by rifampin and antiepileptic drugs — accelerates the metabolism of co-administered substrates and can reduce their therapeutic efficacy to subtherapeutic levels.

Beyond metabolic enzymes, drug transporters including P-glycoprotein (P-gp/ABCB1), organic anion transporting polypeptides (OATPs), organic cation transporters (OCTs), and breast cancer resistance protein (BCRP) modulate drug absorption and tissue distribution. FDA Drug Interaction Guidance (2020) and ICH M12 guideline on drug interaction studies provide frameworks for evaluating transporter-mediated interactions during drug development. For drugs with narrow therapeutic indices — including digoxin (P-gp substrate), methotrexate (OAT substrate), and repaglinide (OATP1B1 substrate) — transporter inhibition can produce clinically significant concentration increases at standard doses.

This interaction checker applies mechanistic interaction classification to provide users with actionable information about the nature and expected clinical significance of identified drug pairs. By explaining whether an interaction is metabolic, transport-mediated, or pharmacodynamic, the tool supports pharmacist counseling and prescriber education beyond simple severity flags. The management recommendations provided reflect consensus from clinical pharmacology texts, FDA prescribing information, and specialty society guidelines, offering a starting point for individualized clinical decision-making.

FAQ

Which CYP450 enzymes are most clinically important for drug interactions?

CYP3A4 is the most clinically important isoform, metabolizing approximately 50% of marketed drugs and subject to inhibition by agents including ketoconazole, ritonavir, clarithromycin, and grapefruit components, and induction by rifampin, carbamazepine, and St. John's Wort. CYP2D6 metabolizes antidepressants, antipsychotics, and opioids; it is inhibited by fluoxetine, paroxetine, and bupropion and is subject to genetic polymorphism affecting up to 10% of Caucasians as poor metabolizers. CYP2C9 metabolizes warfarin, phenytoin, and NSAIDs; it is inhibited by fluconazole and amiodarone. CYP2C19 is relevant for proton pump inhibitors and clopidogrel; poor metabolizer status impairs clopidogrel bioactivation and reduces antiplatelet efficacy.

What is the significance of P-glycoprotein in drug interactions?

P-glycoprotein (P-gp), encoded by the ABCB1 gene, is an efflux transporter expressed in the intestine, blood-brain barrier, kidneys, and liver that actively pumps drugs out of cells, limiting their absorption and CNS penetration. Inhibition of P-gp by agents such as verapamil, amiodarone, or ritonavir increases plasma concentrations of P-gp substrates including digoxin, dabigatran, and many HIV medications. Induction of P-gp by rifampin decreases substrate exposure. FDA Drug Interaction Guidance recommends clinical evaluation of P-gp-mediated interactions for new molecular entities when in vitro data suggests P-gp substrate or inhibitor status.

How do drug interactions affect anticoagulant therapy?

Anticoagulant therapy is among the highest-risk areas for drug interactions because the therapeutic window for agents like warfarin is narrow and interaction consequences include life-threatening bleeding or thromboembolism. Warfarin's anticoagulant effect is amplified by CYP2C9 inhibitors (fluconazole, amiodarone), CYP2C9/2C19 substrates competing for metabolism, and agents with intrinsic antiplatelet or anticoagulant activity (NSAIDs, aspirin). Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban are CYP3A4 and P-gp substrates; concomitant inhibitors increase bleeding risk while inducers reduce efficacy. FDA labeling for all anticoagulants includes comprehensive drug interaction tables requiring clinical monitoring.

What is pharmacokinetic variability and how does it affect interactions?

Pharmacokinetic variability refers to inter-individual differences in drug absorption, distribution, metabolism, and excretion that alter plasma drug concentrations for a given dose. Sources include genetic polymorphisms (CYP2D6, CYP2C19 poor vs. extensive metabolizer phenotypes), age-related decline in renal and hepatic function, body composition affecting volume of distribution, and disease states impairing drug clearance. Drug interactions that inhibit metabolizing enzymes have greater impact in extensive metabolizers who rely heavily on that enzyme, while genetic poor metabolizers may show less additional impact from inhibition because baseline metabolism is already impaired.

How quickly do CYP inhibition-based interactions develop?

CYP inhibition-based interactions typically develop rapidly, often within 24 to 48 hours of initiating the inhibitor, because the mechanism involves competitive or mechanism-based blockade of the enzyme rather than changes in enzyme quantity. Mechanism-based inhibitors such as erythromycin, diltiazem, and paroxetine that form irreversible enzyme-drug complexes may show effects within the first dose. In contrast, CYP induction-based interactions develop more slowly — typically over one to two weeks — because induction requires upregulation of enzyme synthesis. Similarly, the offset of induction takes one to two weeks after the inducer is discontinued, while offset of competitive inhibition is more rapid, paralleling the inhibitor's elimination half-life.